newsfilter
← Latest News
GlobeNewswire·

TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR) (TCR2 or the Company), a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for